李　燕，蒋　刚，林　庆，张明明，陶　铸



恩替卡韦联合转移因子治疗慢性乙肝的效果观察

李燕，蒋刚，林庆，张明明，陶铸

目的观察恩替卡韦联合转移因子对慢性乙肝患者病毒-DNA（HBV DNA）转阴率及免疫功能的影响。方法选取我院收治的100例慢性乙肝患者作为研究对象，随机分为对照组与观察组，每组50例。对照组单用恩替卡韦治疗，观察组则在此基础上加用转移因子口服液治疗，比较两组HBV DNA、HBeAg转阴率，治疗前后HBsAg、HBeAg水平及免疫功能指标的变化。结果治疗3、6个月后，观察组HBeAg转阴率分别为60.0%、72.0%，HBV DNA转阴率分别为32.0%、50.0%，二者转阴率均明显高于对照组（P＜0.05）；观察组HBsAg水平分别为（2.9±0.3）IgIU/ml、（2.3±0.2）IgIU/ml，HBeAg水平为（205.4±66.3）S/CO、（188.6±34.7）S/CO，均显著低于同时间对照组（P＜0.05）；与治疗前相比，对照组CD4+和CD8+水平及CD4+/CD8+比值无显著变化，而观察组CD4+水平和CD4+/CD8+比值显著升高，CD8+水平明显降低（P＜0.05）。结论恩替卡韦联合转移因子口服液治疗慢性乙肝，可提高患者HBV DNA及HBeAg转阴率，改善其HBsAg及HBeAg水平，强化患者免疫功能，值得推广。

慢性乙肝；恩替卡韦；转移因子；免疫功能

[Abstract]Objective To observe the effects of entecavir combined with transfer factor on the negative conversion ratio and immune function of chronic hepatitis B virus-DNA(HBV DNA).Methods 100 patients with chronic hepatitis B were selected as research objects and random ly divided into control and observation groupswith 50 cases in each group.The control group was treated with entecavir alone,while the observation group was additionally treated with transfer factor oral liquid based on the same treatment as the control group.Comparison wasmade in the negative conversion ratios of HBV DNA and HBeAg and the changes in HBsAg and HBeAg levels and immune function indexes before and after the treatment.Results Three and six months after the treatment, the negative conversion ratios of HBeAg in the observation group were 60.0%and 72.0%,and those of HBV DNA were 32.0%and 50.0%,respectively.Those ratios in the observation group were all higher than those in the control group(P＜0.05).The HBsAg levels in the observation group were(2.9±0.3)IgIU/m l and(2.3±0.2)IgIU/m l,respectively,and the HBeAg levels were(205.4±66.3)S/CO and(188.6±34.7)S/CO.Those levels in the observation group were significantly lower than those at the same time period in the control group(P＜0.05).Compared with the levels before the treatment,the CD4+and CD8+levels and the radio of CD4+to CD8+in the control group had no significantly changes.While the CD4+levels and the radio of CD4+to CD8+in the observation group increased significantly,and its CD8+levels significantly decreased(P＜0.05).Conclusion Entecavir combined with transfer factor oral liquid for the treatmentof chronic hepatitis B can improve the negative conversion ratios of HBV DNA and HBeAg,improve the HBsAg and HBeAg levels,and strengthen the immune function of patients.It isworthy of promotion.

[Keywords]chronic hepatitis B;entecavir;transfer factor;immune function

慢性乙肝在我国有较高的发病率。据统计资料显示，我国乙肝病毒携带者占全球范围的30%，其中约有10%的患者可能转变为慢性乙肝，严重者甚至可能进展为肝癌[1]。目前对慢性乙肝的治疗多采用护肝、抗病毒治疗等方式，包括核苷酸、干扰素类药物。其中干扰素主要通过发挥抗病毒、调节免疫等双重作用，疗效持久；核苷酸类药物则有其给药方便的优势，但长期用药停用后可能导致疾病复发[2-3]。基于此，为探讨治疗慢性乙肝的有效方案，我院对收治的100例患者展开了对照分析，现报道如下。……